8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types. HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System - Cutis Laxa Facialis, Xeroderma | Phase 4 | Completed | Austin Institute for Clinical Research | 27 | 2023-11-20 | 2024-10-24 |
| A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain Hemoporfin PDT - Port-wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 40 | 2020-05-27 | 2023-12-20 |
| A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology Haemoblock, Placebo - Vascular Diseases, Vascular Malformation | Phase 4 | Completed | Center for Vascular Pathology, Moscow | 200 | 2020-01-01 | 2021-11-04 |
| Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD) Kybella - Deformity; Skin, Fat Redistribution | Phase 4 | Completed | The Maas Clinic | 37 | 2018-02-20 | 2026-10-19 |
| Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Hemoporfin - Port-Wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 501 | 2017-08-31 | 2023-12-20 |
| A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain Hemoporfin PDT - Port-wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 24 | 2017-08-02 | 2020-08-13 |
| Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. Retapamulin Ointment, 1% - Skin Infections, Bacterial | Phase 4 | Completed | GlaxoSmithKline | 60 | 2007-09-01 | 2016-12-28 |
| Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type celiprolol, Control - EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 54 | 2003-10-01 | 2013-01-16 |
Port-Wine Stain (4) · Capillary Malformation-Arteriovenous Malformation (1) · Capillary Malformations, Congenital, 1 (1) · Cardiovascular Diseases (1) · Cellulitis (1) · Chromosome 2q31.2 Deletion Syndrome (1) · Ehlers-Danlos Syndrome (1) · Ehlers-Danlos Syndrome, Type IV (1) · Ichthyosis (1) · Impetigo (1) · Infections (1) · Lipodystrophy (1) · Skin Diseases (1) · Sturge-Weber Syndrome (1)
Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Skin and Connective Tissue Diseases (8) · Skin Diseases (7) · Connective Tissue Diseases (2) · Aneurysm (1) · Angiomatosis (1) · Aortic Dissection (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Collagen Diseases (1) · Death (1)
Celiprolol (1) · Deoxycholic Acid (1) · hematoporphyrin monomethyl ether (1)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (3) · Assistance Publique - Hôpitaux de Paris (1) · Austin Institute for Clinical Research (1) · Center for Vascular Pathology, Moscow (1) · GlaxoSmithKline (1) · The Maas Clinic (1)
China (3) · United States (3) · Argentina (1) · Chile (1) · Costa Rica (1) · Germany (1) · Mexico (1) · Netherlands (1) · Russia (1) · South Africa (1) · Taiwan (1)
Jining Tao (2) · Alexander Plotkin, PhD (1) · Corey S Maas, M.D. (1) · Dmitry V Romanov, MD (1) · Edward Lain, MD, MBA (1) · Ekaterina M Listovskaya, BSc (1) · Lin Ma, MD (1) · Xuejun Zhu (1)